Teledoc (TDOC) Gets a $7 Price Target From Barclays: Can It Double From Recent Lows?

Teladoc Health (NYSE:TDOC) has staged a notable betterment disconnected its lows, but the banal remains nether important unit from its longer-term trajectory. Shares are up 1.37% implicit the past week and person gained 3.83% implicit the past month, yet they stay down 21.21% year-to-date and astir 36% implicit the past year.

The banal sits good beneath its 52-week precocious of $9.77, and its five-year diminution of 96.85% from a highest adjacent $176.89 tells the broader communicative of a institution inactive searching for its footing. Most analysts support cautious stances, with the Street statement people astatine $7.12 and 21 of 27 analysts standing the banal a Hold.

Barclays precocious chopped its terms people connected Teladoc to $7 from $8.50, maintaining an Equal Weight standing pursuing a gathering with management. From the existent terms of $5.57, that people inactive implies upside of much than 25%, landing astir successful enactment with the broader Street consensus. But tin TDOC realistically scope $7 by extremity of 2026?

Have You work The New Report Shaking Up Retirement Plans? Americans are answering 3 questions and galore are realizing they tin retire earlier than expected.

Barclays acknowledges pockets of optimism successful the business, peculiarly successful International and the insured broadside of BetterHelp, but frames its cautious stance astir a institution transitioning its exemplary successful a competitory conception of the market. That modulation is disposable successful the numbers: BetterHelp gross fell 7% year-over-year successful Q4 2025, and 2026 guidance calls for BetterHelp gross to diminution a further 0.5% to 7.0% arsenic the conception shifts toward insurance-based delivery.

1. BetterHelp Insurance Scaling: The institution is present unrecorded successful 20 states positive Washington, D.C. with much than 120 cardinal covered lives secured. Insurance sessions are generating an annualized gross tally complaint of implicit $40 million, with a 2026 people of $75 cardinal to $90 million.

2. International Revenue Growth: International gross surged 19% year-over-year to $125 cardinal successful Q4 2025, representing astir 24% of full conception gross for full-year 2025.

3. Improving Profitability Trajectory: Adjusted EBITDA improved 12% to $83.8 cardinal successful Q4, and the institution generated $167 cardinal successful escaped currency travel for full-year 2025. Net nonaccomplishment narrowed 48% year-over-year successful the quarter.